TherapeuticsMDe VagiCap treatment performs well in two studies

TherapeuticsMD's (TXMD) Estradiol VagiCap vaginal capsule for the treatment of vulvar vaginal atrophy (VVA) in post-menopausal women performed well in two trials when compared with NovoNordisks (NVO) Vagifem.

The results of the studies showed substantially lower systemic exposure to the estradiol hormone of the VagiCap - also known as TX 12-004-HR - vs Vagifem.

VVA affects up to 50% of postmenopausal women and is a result of a decrease in estrogen.

TherapeuticsMD's shares are +7.8%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs